Top
News
Change the future
with cell therapy
Our aim is to develop new cell therapies
using “hematopoietic stem cells”.
Hematopoietic stem cells (HSCs) are the stem cells that are the very source of blood.
Our aim is to develop new cell therapies in order to treat blood cancer,
intractable blood diseases and genetic disorders.
The development of new cell therapies in the fight against leukemia and other blood cancers and genetic disorders
We are working on the development of next-generation cell therapy products that will utilize the unique properties of umbilical cord blood and peripheral blood, by expanding them in large quantities.
Successful in-vitro expansion of functional hematopoietic stem cells
We have succeeded in developing technology for the mass propagation of functional HSCs with blood reconstruction ability. In addition, since the technology does not use animal-derived components such as albumin and cytokines, HSCs can be propagated in large quantities with high quality and at low cost.
A growing need for the application of HSCs in cell therapy
In addition to providing new therapeutic options for the HSC transplantation treatments that are being performed today, we are also working on applications in the field of gene therapy, which has seen much active development in recent years.
-
R&DTokyo Medical and Dental University and Celaid Therapeutics Inc. Joint Research Agreement on Research and Development of Gene-modified Cell Thera…
-
newsCelaid Therapeutics Inc has been selected for the Silicon Valley Immersion Program sponsored by NEDO
-
newsSpeaker at Biopharmaceutical EXPO
-
financing
Celaid has raised 1.2 billion yen in its Series A financing round to advance HSC-based cell and gene therapies and platform
-
R&D
FBRI and Celaid have executed a collaborative research agreement for vascular regeneration products derived from human hematopoietic stem cells
-
R&D
Chosen for the New Energy and Industrial Technology Development Organization (NEDO) Deep Tech Startup Support Project (DTSU)